In the past, other relevant approaches have been tested aimed at improving first-line outcomes for patients with advanced EGFR mutant NSCLC, such as the combination of vascular endothelial growth factor inhibitors with first-generation EGFR TKIs. Here, EGFR is linked to non-small cell lung carcinoma.